Lokelma Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Concise Prescribing Info

Contents

Sodium zirconium cyclosilicate

Indications/Uses

Hyperkalaemia in adults.

Click to view Lokelma detailed prescribing information

Dosage/Direction for Use

Correction phase: Initially 10 g tid. Continue for additional 24 hr if patients are still hyperkalaemic after 48 hr of treatment. Maintenance phase: Initially 5 g once daily, w/ possible titration up to 10 g once daily, or down to 5 g once every other day as needed to maintain normal K level. Max: 10 g once daily. Patient on dialysis Initially 5 g once daily on non-dialysis days. Dose may be titrated up or down wkly based on pre-dialysis serum K value after long inter-dialytic interval. Adjust dose at 1-wk interval in increments of 5 g up to 15 g once daily on non-dialysis days.

Click to view Lokelma detailed prescribing information

Overdosage

View Lokelma overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food: Stir well w/ water & take while still cloudy.

Contraindications

Hypersensitivity.

Click to view Lokelma detailed prescribing information

Special Precautions

Discontinue treatment in patients w/ severe hypokalaemia. Hypokalaemia; lengthening of QT interval. Risk for intestinal perforation. Patients on low salt diet. Monitor serum K levels regularly during treatment; wkly during dose adjustment & regularly (eg, mthly or more frequently) once normokalaemia is established; after changes are made to medicinal products that affect serum K conc (eg, renin-angiotensin-aldosterone system inhibitors or diuretics) & after dose titration. Risk of interaction w/ X-rays. Avoid use during pregnancy. Childn & adolescents <18 yr.

Click to view Lokelma detailed prescribing information

Use In Pregnancy & Lactation

Click to view Lokelma detailed prescribing information

Adverse Reactions

Hypokalaemia; constipation; oedema related events eg, fluid retention, generalised & localised oedema, oedema, hypervolaemia, peripheral oedema & swelling.

Click to view Lokelma detailed prescribing information

Drug Interactions

Changes in solubility & absorption kinetics of medicinal products w/ pH-dependent bioavailability. Lowered C_max & AUC of dabigatran; tacrolimus. Possible raised gastric pH w/ azole antifungals (ketoconazole, itraconazole, posaconazole), anti-HIV agents (atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir, rilpivirine) & tyrosine kinase inhibitors (erlotinib, dasatinib, nilotinib).

Click to view Lokelma detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Lokelma detailed prescribing information

Storage

View Lokelma storage conditions for details to ensure optimal shelf-life.

Description

View Lokelma description for details of the chemical structure and excipients (inactive components).

Action

View Lokelma mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Other Therapeutic Products

ATC Classification

V03AE10 - sodium zirconium cyclosilicate ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.

Thai FDA Category

Presentation/Packing

Form

Lokelma powd for oral susp 5 g

Packing/Price

30 × 1's

Lokelma

sodium zirconium cyclosilicate

Manufacturer:

Andersonbrecon Inc

Distributor:

Zuellig Pharma

Marketer:

AstraZeneca